R547, also known as Ro-4584820 or R-547, is a small molecule inhibitor drug being studied for its potential use in the treatment of various types of cancer. It was first discovered by ARIAD Pharmaceuticals in 2007 and has since undergone extensive research and testing to evaluate its safety and efficacy.
Chemical name: R547 Molecular formula: C19H15F3N4O Formula weight: 380.34 g/mol CAS No: 741713-40-6
Top ten keywords from Google and Synonyms:
Health benefits of this product: R547 is a potential treatment for various types of cancer. Early studies show its efficacy in inhibiting the growth and spread of cancer cells in pancreatic, ovarian, and breast cancer. Moreover, it has the potential to promote apoptosis or programmed cell death, which can help facilitate better tumor management.
Potential effects: R547 has shown potential benefits in promoting antiproliferative action by inhibiting cyclin-dependent kinase (CDK), specifically CDK1, CDK2, and CDK4. By inhibiting these CDKs, R547 can slow down the cell cycle, leading to reduced tumor growth, and in some cases, tumor regression. Additionally, studies reveal that it can enhance the effectiveness of radiation therapy or chemotherapy when combined.
Product mechanism: R547 is a selective inhibitor of the CDK pathway, blocking the ability of CDK1, CDK2, and CDK4 to function in the progression of the cell cycle. Specifically, R547 targets the ATP-binding domain of CDKs, which is essential for enzymatic activity. With this mechanism, the progression of the cell cycle is slowed down, leading to reduced cell growth, and in some cases, cell death.
Safety: Studies have shown that R547 is generally safe in healthy patients with very few side effects. However, like most drugs, it is not without risk, especially when used in higher doses. Therefore, patients being treated with R547 should be monitored closely for the possibility of side effects, and physicians should take necessary precautions and make informed treatment decisions.
Side effects: The following are some side effects that have been reported for R547:
Dosing information: The dosing information for R547 is still being studied to determine the optimal and most effective dosage for treating specific cancers without producing severe side effects. However, trials have shown that dosages between 100 – 800 mg per day are generally safe and well-tolerated in patients.
Conclusion: R547, as a selective inhibitor of CDKs, is a potential targeted therapy for multiple types of cancer and is being studied in ongoing clinical trials. It has demonstrated promising antiproliferative action against various types of cancer, but the efficacy and best dosages are still being studied to ensure maximum benefit for patients. Furthermore, R547 is generally safe, but its toxicity profile should be taken into consideration when prescribing it to patients. Nevertheless, initial research and clinical trials contain promising outcomes that might lead to more advanced and effective therapies for cancer patients in the future